Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Avutometinib With or Without Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
2025-524713-88-00Phase 2Authorised
- Sponsor
- Verastem Oncology
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avutometinib and defactinib in ovarian cancer (2 arms), sponsored by Verastem Oncology. Primary endpoint: Investigator’s determination of ongoing clinical benefit. Planned start Jul 2026; status: authorised.
02
Drugs
avutometinibdefactinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2025-524713-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524713-88-00.